Scipher Medicine, known for its molecular diagnostics in rheumatoid arthritis, is pivoting toward broad precision medicine applications beyond oncology. Under CEO Reg Seeto, the company is leveraging its large non-oncology clinical transcriptomic dataset, amassed through extensive RNA sequencing, to facilitate biomarker discovery and drug development. Scipher has forged multiple data-sharing partnerships, including a recent collaboration with health data platform Savant Bio, which employs AI-driven extraction of clinical variables from unstructured documents. The strategic shift mirrors successful oncology platforms, aiming to fill gaps in immunology and accelerate therapeutic advances across multiple disease areas.